Faculty of Biology, Medicine and Health

The University of Manchester

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities

  Discerning the role of metabolic proteins in nucleus

  Dr A Latif  Applications accepted all year round  Self-Funded PhD Students Only

About the Project

Pancreatic Ductal Adenocarcinoma (PDAC), which develops from cells lining pancreas ducts, represents 95% of all pancreatic cancer cases. In the UK alone, PDAC is the 11th most common cancer with ~10,000 new cases diagnosed every year. It has abysmal life-expectancy with only 7% surviving the first five years[1]. PDAC death rates are constantly on the rise and it is projected to become the second most lethal cancer by 2030[2].

Monocarboxylate transporter 1 (MCT1) is a transmembrane protein involved in cell metabolism and mediates transport of monocarboxylates (such as pyruvate and lactate) in both directions across plasma membrane. Increased plasma membrane expression of MCT1 (PM MCT1) has been reported in several cancer types including pancreatic[8] cancers and are associated with worse prognosis, reduced recurrence-free and overall survival. Interestingly, although nucleus is not a usual location for MCT1 (based on current knowledge on its function), we and others reported nuclear MCT1 (nMCT1) expression in endometrial[7] and soft sarcoma[9]. Both studies showed that patients with nMCT1 have a longer overall survival than the patients without it. Therefore, it is important to improve knowledge on the significance of MCT1 localisation and evaluate its potential effects on treatment outcome for improving PDAC patients’ survival. For this purpose; we aim to 1. subject PDAC tissues to IHC and relate protein localisation to survival (for patients with/without nMCT1), 2. perform RNA-seq on a. BxPC3 (nMCT1 model) and Mia-Paca2 (PM MCT1 model) cells and b. genetically modified PDAC cells over-expressing nMCT1 or PM MCT1, 3. measure sensitivity to chemotherapy(FOLFIRINOX) in nMCT1 expressing cells and 4. test efficacy of MCT1 inhibitors for improving chemotherapy outcome in chemo-resistant PM MCT1 cells.

Eligibility 

Applicants must have obtained or be about to obtain a First or Upper Second class UK honours degree, or the equivalent qualifications gained outside the UK, in a biological discipline including Biology, Neuroscience and allied fields, Pharmacology, Molecular Biology. Applicants with experience in basic molecular techniques and an interest in neurodevelopment are encouraged to apply.

Before you Apply 

Applicants must make direct contact with preferred supervisors before applying. It is your responsibility to make arrangements to meet with potential supervisors, prior to submitting a formal online application.  

How to Apply 

For information on how to apply for this project, please visit the Faculty of Biology, Medicine and Health Doctoral Academy website (https://www.bmh.manchester.ac.uk/study/research/apply/). Informal enquiries may be made directly to the primary supervisor. On the online application form select the appropriate subject title - PhD Neuroscience.

For international students, we also offer a unique 4 year PhD programme that gives you the opportunity to undertake an accredited Teaching Certificate whilst carrying out an independent research project across a range of biological, medical and health sciences. For more information please visit https://www.bmh.manchester.ac.uk/study/research/international-phd/

Your application form must be accompanied by a number of supporting documents by the advertised deadlines. Without all the required documents submitted at the time of application, your application will not be processed and we cannot accept responsibility for late or missed deadlines. Incomplete applications will not be considered. If you have any queries regarding making an application please contact our admissions team [Email Address Removed]  

Equality, Diversity and Inclusion  

Equality, diversity and inclusion is fundamental to the success of The University of Manchester, and is at the heart of all of our activities. The full Equality, diversity and inclusion statement can be found on the website https://www.bmh.manchester.ac.uk/study/research/apply/equality-diversity-inclusion/  

Biological Sciences (4)

Funding Notes

Applications are invited from self-funded students. This project has a Band 2 fee. Details of our different fee bands can be found on our website here: https://www.bmh.manchester.ac.uk/study/research/fees/

References

1. Ayşe Ufuk, Terence Garner, Adam Stevens, Ayşe Latif . ‘Monocarboxylate transporters are involved in extracellulat matrix remodelling in pancreatic ductal adenocarcinoma’. Cancers; 2022; DOI: 10.3390/ cancers14051298.
2. Vanitha N Sivalingam*, Ayşe Latif *, Sarah Kitson, Rhona McVey, Henry Kitchener, Katherine G Finegan, Kay Marshall, Michael Lisanti, Federica Sotgia, Ian J Stratford, Emma J Crosbie. ‘Hypoxia and hyperglycaemia contribute to metformin resistance in endometrial cancer’. *Equal contribution by both authors. British Journal of Cancer (Nature Publishing Group), January 2020.
3. Salem, A., Little, R., Latif, A., Featherstone, A., Babur, M., Peset Martin, I., Cheung, S., Watson, Y., Tessyman, V., Mistry, H., Williams, K., O’Connor, J. ‘Oxygen enhanced-MRI is feasible, repeatable and detects radiotherapy induced change in hypoxia in xenograft models and in patients with non-small cell lung cancer’, Clinical Cancer Research.2019 Mar; DOI:10.1158/1078-0432.CCR-18-3932
4. Ayşe Latif, Amy L Chadwick, Sarah J Kitson, Hannah J Gregson, Vanitha N Sivalingam, James Bolton, Rhona J McVey, Stephen A Roberts, Kay M Marshall, Kaye J Williams, Ian J Stratford, Emma J Crosbie. ‘Monocarboxylate Transporter 1 (MCT1) expression is an independent prognostic marker in endometrial cancer’. BMC Clinical Pathology; 2017 Dec; 17(27)
5.Andrew James, Waseema Patel, Zohra Butt, Magretta Adiarnah, Raga Dakhel, Ayşe Latif, Caroline Uggenti, Eileithyia Swanton, Hiromi Imamura, Ajith Siriwardena and Jason Bruce. ‘The plasma membrane calcium pump in pancreatic cancer cells exhibiting the Warburg effect relies on glycolytic ATP’. The Journal of Biological Chemistry; 2015 Aug; 290(41): 24760-24771.

Open Days


Where will I study?

Faculty of Biology, Medicine and Health

Tackle real world challenges, make a difference, and elevate your career with postgraduate research in the Faculty of Biology, Medicine and Health at Manchester. From biochemistry to neuroscience, cancer sciences to medicine, audiology to mental health and everything in between, we offer a wide range of postgraduate research projects, programmes and funding which will allow you to immerse yourself in an area of research you’re passionate about.

Why study at Faculty of Biology, Medicine and Health?

Ranked the best place to live in the UK (The Economist Global Liveability Index, 2022), Manchester boasts world-class culture, iconic sports, a thriving music and food scene, and much more. It's not just a place to research, it's a place to call home.

Experience PhD life as part of a diverse postgraduate research community of more than 1,000 postgraduate researchers at the 29th most international university in the world (Times Higher Education, 2023).

With 93% of research activity at the University rated as 'world-leading' or 'internationally excellent' (Research Excellence Framework, 2021), you'll get the chance to have an impact on global health and science challenges.

1000+

postgraduate students

117

PhDs

6

ranked in UK - QS (2025)

Manchester  United Kingdom

main campus

Upcoming Open Days & Webinars


About Faculty of Biology, Medicine and Health

At Manchester, postgraduate researchers are at the heart of our mission to tackle pressing global challenges in biological, medical and healthcare sciences - and you could be too.

By choosing Manchester for your postgraduate research, you’ll be joining a university with an exceptional research reputation, where 93% of research is world-leading or internationally excellent (REF, 2021) and where your work will have real-world impact.

You’ll research in world-class facilities alongside leading experts at the forefront of innovation, collaborating across disciplines to pioneer new treatments, advance scientific knowledge, and improve healthcare globally.

Supported by our dedicated Doctoral Academy and strong industry links, you'll experience PhD life in a vibrant, welcoming and diverse postgraduate research community.

And you’ll leave with the specialist knowledge, research experience and transferable skills that will shape your future in academia, research or industry.


Main campus

The University of Manchester

Manchester

North West

United Kingdom

PhD saved sucessfully

(BBSRC NWD) Developing biosensors to detect phage replication

Bacteriophages are viruses that infect bacteria, replicate inside them, and then burst the cells to release new phages. Their ability to self-replicate and kill bacteria makes them a potential alternative to traditional antibiotics. Read more
More details

(BBSRC NWD) Epigenetic mechanisms linking maternal inflammation-induced placental and fetal brain changes to adult behavioural impairment in a neurodevelopmental rat model

This project has the primary aim to establish the biological and molecular mechanisms that underpin the increased risk for neurodevelopmental disorders following exposure of the developing fetus in utero to maternal inflammation from maternal immune activation following an infection during pregnancy. Read more
More details

(BBSRC NWD) Function of somatosensory cortex during natural behaviour

We recently developed novel interdisciplinary methods that make it possible to study neural mechanisms of sensation in the brains of mice during natural behaviour – that is when they are free to move (Storchi et al, 2020; Orlowska-Feuer et al, 2022; Gantar et al, 2024; Petersen et al, 2022). Read more
More details

(BBSRC NWD) Harnessing organic catalysts for precision interaction mapping in ubiquitin-like systems

This PhD project focuses on the development and application of innovative tools to achieve high-resolution mapping of protein-protein interactions (PPIs) within ubiquitin-like protein (UBL) systems, addressing a critical gap in understanding cellular signalling. Read more
More details